Abstract
Evaluation of: Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br. J. Cancer 105(11), 1635-1639 (2011). The results achieved with targeted therapy have changed the natural course of kidney cancer not amenable to local therapy. Sunitinib, bevacizumab and pazopanib are approved in the first-line setting for patients at good/intermediate prognosis, while temsirolimus should be the first-line agent to be used in patients at poor prognosis. The oncology community has been eagerly awaiting results as far as second-line treatment is concerned. The RECORD-1 and AXIS trials provided evidence in favor of everolimus and axitinib, respectively, in patients pretreated with VEGF-directed agents. As the number of available agents grows, so does the possibility of using multiple lines of therapy with a potential benefit in overall survival. The third-line setting has been poorly investigated, and no comparative prospective trials are presently available. Retreatment with VEGF-directed therapy may be an option in everolimus-pretreated patients, with the possibility that mTOR inhibitors may reverse resistance to VEGF-directed therapy. Grunwald et al. presented retrospective data showing that retreatment with VEGF-directed targeted agents, including sunitinib, bevacizumab/interferon, dovitinib and sorafenib, was associated with a progression-free survival time of approximately 5 months. Although the evidence provided by retrospective studies is weak, their role in highlighting matters of clinical relevance deserving investigation is undoubtful, as demonstrated by the retrospective study discussed in this paper.
| Original language | English |
|---|---|
| Pages (from-to) | 331-333 |
| Number of pages | 3 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2012 |
Fingerprint
Keywords
- kidney cancer
- retrospective study
- sorafenib
- sunitinib
- targeted therapy
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
Cite this
How to carry out retrospective studies in metastatic renal cell cancer : Two caveats that should be avoided. / Di Lorenzo, Giuseppe; Ferro, Matteo; Buonerba, Carlo.
In: Expert Review of Anticancer Therapy, Vol. 12, No. 3, 03.2012, p. 331-333.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - How to carry out retrospective studies in metastatic renal cell cancer
T2 - Two caveats that should be avoided
AU - Di Lorenzo, Giuseppe
AU - Ferro, Matteo
AU - Buonerba, Carlo
PY - 2012/3
Y1 - 2012/3
N2 - Evaluation of: Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br. J. Cancer 105(11), 1635-1639 (2011). The results achieved with targeted therapy have changed the natural course of kidney cancer not amenable to local therapy. Sunitinib, bevacizumab and pazopanib are approved in the first-line setting for patients at good/intermediate prognosis, while temsirolimus should be the first-line agent to be used in patients at poor prognosis. The oncology community has been eagerly awaiting results as far as second-line treatment is concerned. The RECORD-1 and AXIS trials provided evidence in favor of everolimus and axitinib, respectively, in patients pretreated with VEGF-directed agents. As the number of available agents grows, so does the possibility of using multiple lines of therapy with a potential benefit in overall survival. The third-line setting has been poorly investigated, and no comparative prospective trials are presently available. Retreatment with VEGF-directed therapy may be an option in everolimus-pretreated patients, with the possibility that mTOR inhibitors may reverse resistance to VEGF-directed therapy. Grunwald et al. presented retrospective data showing that retreatment with VEGF-directed targeted agents, including sunitinib, bevacizumab/interferon, dovitinib and sorafenib, was associated with a progression-free survival time of approximately 5 months. Although the evidence provided by retrospective studies is weak, their role in highlighting matters of clinical relevance deserving investigation is undoubtful, as demonstrated by the retrospective study discussed in this paper.
AB - Evaluation of: Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br. J. Cancer 105(11), 1635-1639 (2011). The results achieved with targeted therapy have changed the natural course of kidney cancer not amenable to local therapy. Sunitinib, bevacizumab and pazopanib are approved in the first-line setting for patients at good/intermediate prognosis, while temsirolimus should be the first-line agent to be used in patients at poor prognosis. The oncology community has been eagerly awaiting results as far as second-line treatment is concerned. The RECORD-1 and AXIS trials provided evidence in favor of everolimus and axitinib, respectively, in patients pretreated with VEGF-directed agents. As the number of available agents grows, so does the possibility of using multiple lines of therapy with a potential benefit in overall survival. The third-line setting has been poorly investigated, and no comparative prospective trials are presently available. Retreatment with VEGF-directed therapy may be an option in everolimus-pretreated patients, with the possibility that mTOR inhibitors may reverse resistance to VEGF-directed therapy. Grunwald et al. presented retrospective data showing that retreatment with VEGF-directed targeted agents, including sunitinib, bevacizumab/interferon, dovitinib and sorafenib, was associated with a progression-free survival time of approximately 5 months. Although the evidence provided by retrospective studies is weak, their role in highlighting matters of clinical relevance deserving investigation is undoubtful, as demonstrated by the retrospective study discussed in this paper.
KW - kidney cancer
KW - retrospective study
KW - sorafenib
KW - sunitinib
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84857852978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857852978&partnerID=8YFLogxK
U2 - 10.1586/era.11.215
DO - 10.1586/era.11.215
M3 - Article
C2 - 22369324
AN - SCOPUS:84857852978
VL - 12
SP - 331
EP - 333
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 3
ER -